UPTRAVI® (selexipag)—GRIPHON Trial Included
Patients Treated With Monotherapy, Dual- and
THE TREATMENT EFFECT ON TIME TO FIRST DISEASE PROGRESSION EVENT
WAS CONSISTENT IRRESPECTIVE OF PAH BACKGROUND THERAPY1
*Dual combination with either an ERA or a PDE-5i. Triple combination with an ERA and a PDE-5i.
Note: The figure above presents effects in various subgroups, all of which are baseline characteristics and all were prespecified; various other subgroup comparisons (not shown) were made. The 99% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.